Ataciguat

---

Ataciguat is a novel anthranilic acid derivative that belongs to a  structural class of soluble Guanyl cyclase (sGC) activators that can activate the oxidized form of sGC. Ataciguat has undergone extensive  pre-clinical and clinical development  for treatment of the progression of CAVS. The drug and its application in CAVS is now licensed to RSF Bio for further development through clinical trials and if successful, for future  commercialization